Marktanalyse - Fibromyalgia - Pipeline Review, H1 2017

Global Markets Direct
02.2017
62 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Fibromyalgia - Pipeline Review, H1 2017


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibromyalgia — Pipeline Review, H1 2017, provides an overview of the Fibromyalgia (Central Nervous System) pipeline landscape.

Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Symptoms include fatigue, depression, headaches, and pain or cramping in the lower abdomen. The predisposing factors include family history, rheumatoid arthritis or lupus. Treatment includes pain relievers, antidepressants and anti-seizure drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibromyalgia — Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fibromyalgia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibromyalgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fibromyalgia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 6, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Fibromyalgia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Fibromyalgia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Fibromyalgia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Fibromyalgia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Fibromyalgia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Fibromyalgia (Central Nervous System)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Fibromyalgia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Fibromyalgia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Fibromyalgia - Overview

Fibromyalgia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Fibromyalgia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Fibromyalgia - Companies Involved in Therapeutics Development

Astellas Pharma Inc

Daiichi Sankyo Company Ltd

Immune Therapeutics Inc

Innovative Med Concepts LLC

Jiangsu Hengrui Medicine Co Ltd

KPI Therapeutics Inc

Merck & Co Inc

Pfizer Inc

SWITCH Biotech LLC

Theravance Biopharma Inc

Vitality Biopharma Inc

Zynerba Pharmaceuticals Inc

Fibromyalgia - Drug Profiles

(celecoxib + famciclovir) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AS-1069562 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-0819 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-8062 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mirogabalin besylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mirtazapine ODT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Block Voltage-Dependent N-Type Calcium Channel for Central Nervous System - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pregabalin CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pregabalin SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SWT-06101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-9855 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

U-2902 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZYN-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fibromyalgia - Dormant Projects

Fibromyalgia - Discontinued Products

Fibromyalgia - Product Development Milestones

Featured News & Press Releases

Oct 17, 2016: Zynerba Provides Clinical Update for Lead Development Candidate ZYN001

Jan 28, 2016: Innovative Med Concepts Announces Receipt of FDA Fast Track Designation for IMC-1, a Novel Treatment for Fibromyalgia

Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin

Nov 18, 2014: Novel Fibromyalgia Treatment Shows Promise In Study

Apr 30, 2014: Theravance Announces Positive Results From a Phase 2 Study of TD-9855 in Patients With Fibromyalgia

Dec 04, 2012: Theravance Initiates Phase II Study With TD-9855 For Treatment Of Fibromyalgia

Nov 27, 2012: Intellipharmaceutics Announces Results Of Initial Phase I Clinical Trial Of Controlled-release Pregabalin

Nov 19, 2012: Pfizer Reports Top-line Results Of Phase III Study Evaluating Pregabalin Controlled-release As Treatment For Patients With Fibromyalgia

Jul 23, 2012: Pfizer Reports Top-Line Results Of EU Post-Authorization Safety And Efficacy Study Of Lyrica’s Discontinuation Effects In Patients With Generalized Anxiety Disorder

Feb 02, 2009: UCB Announces Top-Line Outcomes For Proof-Of-Concept Studies

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer





List of Tables

Number of Products under Development for Fibromyalgia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Fibromyalgia - Pipeline by Astellas Pharma Inc, H1 2017

Fibromyalgia - Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Fibromyalgia - Pipeline by Immune Therapeutics Inc, H1 2017

Fibromyalgia - Pipeline by Innovative Med Concepts LLC, H1 2017

Fibromyalgia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017

Fibromyalgia - Pipeline by KPI Therapeutics Inc, H1 2017

Fibromyalgia - Pipeline by Merck & Co Inc, H1 2017

Fibromyalgia - Pipeline by Pfizer Inc, H1 2017

Fibromyalgia - Pipeline by SWITCH Biotech LLC, H1 2017

Fibromyalgia - Pipeline by Theravance Biopharma Inc, H1 2017

Fibromyalgia - Pipeline by Vitality Biopharma Inc, H1 2017

Fibromyalgia - Pipeline by Zynerba Pharmaceuticals Inc, H1 2017

Fibromyalgia - Dormant Projects, H1 2017

Fibromyalgia - Dormant Projects, H1 2017 (Contd..1), H1 2017

Fibromyalgia - Discontinued Products, H1 2017





List of Figures

Number of Products under Development for Fibromyalgia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus